Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Featured trial
CAHtalyst Study: A Research Study for Adults with Classic Congenital Adrenal Hyperplasia (CAH)

The CAHtalyst Study is a clinical research study evaluating an investigational medication for adults 18 years of age and older who have been diagnosed with classic congenital adrenal hyperplasia

classic congenital adrenal hyperplasia
congenital adrenal hyperplasia
  • 50 views
  • 23 Nov, 2020
  • 1 location
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric patients with classic congenital

21-ohd
deficiency
classic congenital adrenal hyperplasia
  • 0 views
  • 22 Apr, 2022
  • 24 locations
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.

21-ohd
oral hydrocortisone
classic congenital adrenal hyperplasia
  • 1 views
  • 27 May, 2022
  • 1 location
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal Hyperplasia.

glucocorticoids
replacement therapy
prednisone
glucocorticoid therapy
deficiency
  • 0 views
  • 25 Mar, 2022
A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])

This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 [NCT04783181] gene therapy trial with BBP-631.

21-ohd
deficiency
classic congenital adrenal hyperplasia
  • 0 views
  • 10 Mar, 2022
  • 1 location